天野 虎次 (アマノ トラジ)

北海道大学病院 医療・ヘルスサイエンス研究開発機構特任助教
総合イノベーション創発機構ワクチン研究開発拠点特任助教

研究者基本情報

■ 学位
  • 博士(医学), 北海道大学
  • 公衆衛生学修士(専門職), 東京大学
■ URL
researchmap URLホームページURL■ ID 各種
J-Global ID■ 研究キーワード・分野
研究分野
  • ライフサイエンス, 腫瘍診断、治療学
  • ライフサイエンス, ゲノム生物学

研究活動情報

■ 論文
  • Comprehensive Cancer Genomic Profiling and Germline Predisposition Analysis in Pediatric Cancer: Insights From the Hokkaido Pediatric Cancer Consortium, Japan
    Yusuke Saito; Yukayo Terashita; Toraji Amano; Minako Sugiyama; Kazumi Oura; Masataka Hasegawa; Jutaro Abe; Shinsuke Hirabayashi; Yuko Cho; Shin Ariga; Kanako Hagio; Yoshihito Ohhara; Junko Kikuchi; Yukitomo Ishi; Shigeru Yamaguchi; Hiromi Kanno-Okada; Emi Takakuwa; Zen-Ichi Tanei; Yuka Shibata; Mio Mukainakano; Honami Fujita; Kanako C. Hatanaka; Yutaka Hatanaka; Akira Takebayashi; Yusuke Akane; Masaki Yamamoto; Takeo Sarashina; Shinya Tanaka; Takahiro Yamada; Ichiro Kinoshita; Atsushi Manabe
    PEDIATRIC BLOOD & CANCER, 72, S850, S850, 2025年12月
    英語
  • 日本のがんゲノム医療におけるアカデミア・アセンブリの設立と成果
    内藤 陽一; 天野 虎次; 小峰 啓吾; 鹿毛 秀宣; 林 秀幸; 角南 久仁子; 小山 隆文; 下井 辰徳; 向原 徹; 近藤 千晶; 吉波 哲大; 遠西 大輔; 馬場 英司; 深田 一平
    日本癌治療学会学術集会抄録集, 63回, FR2, 3, (一社)日本癌治療学会, 2025年10月
    英語
  • Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan.
    Takuro Noguchi; Shin Ariga; Rika Moku; Junko Kikuchi; Toraji Amano; Takuya Maeda; Kosuke Ishikawa; Taku Maeda; Akihiko Shiiya; Tomohiro Goda; Yoshihito Ohhara; Kanako Hagio; Yusuke Saito; Kanako C Hatanaka; Yutaka Hatanaka; Jun Taguchi; Satoshi Takeuchi; Yasushi Shimizu; Ichiro Kinoshita
    JCO precision oncology, 9, e2400437, 2025年01月, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: Precision medicine plays an important role in the treatment of patients with advanced melanoma. Despite its high incidence in White patients, advanced melanoma is rare in Asian countries, hampering prospective clinical trials targeting the Asian population. This retrospective study aimed to elucidate the real-world molecular diagnoses and outcomes of Japanese patients with melanoma using comprehensive genome profiling (CGP). MATERIALS AND METHODS: Patients with melanoma who completed standard anticancer medical treatments (including those expected to complete the treatments) underwent CGP, which is covered by the National Health Insurance. We analyzed the results and clinical annotations of 569 patients registered before August 2023 in a national database. RESULTS: Skin, mucosal, and uveal melanomas accounted for 64%, 28%, and 7% of cases, respectively. Patients with BRAF, NRAS, NF1, and KIT variants represented 25%, 20%, 17%, and 17%, respectively. Eighty-two percent of BRAF, 97% of NRAS, 69% of NF1, and 54% of KIT were actionable alterations (ie, BRAF classes I, II, and III, NRAS Q61, G12, G13, NF1 loss-of-function, KIT gain-of-function variants). BRAF V600E/K variants occurred in 22% of skin and 2% of mucosal melanomas, but not in uveal melanomas. The mean tumor mutation burden in cutaneous melanomas was 4.2 variants/Mb. Patients previously treated with BRAF-targeted therapy harbored amplifications of BRAF and cell cycle genes more frequently than therapy-naive patients. Thirty-six patients (6.3%) were treated following the molecular tumor board (MTB) recommendations. CONCLUSION: Actionable gene alterations in BRAF, NRAS, NF1, and KIT are common in Japanese patients with melanoma. However, few patients were treated according to the MTB recommendations, suggesting that there is an unmet need to increase accessibility to gene-matched clinical trials in Japan.
  • Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.
    Kanako Hagio; Junko Kikuchi; Kohichi Takada; Hiroki Tanabe; Minako Sugiyama; Yoshihito Ohhara; Toraji Amano; Satoshi Yuki; Yoshito Komatsu; Takahiro Osawa; Kanako C Hatanaka; Yutaka Hatanaka; Takashi Mitamura; Ichiro Yabe; Yoshihiro Matsuno; Atsushi Manabe; Akihiro Sakurai; Atsushi Ishiguro; Masato Takahashi; Hiroshi Yokouchi; Hirohito Naruse; Yusuke Mizukami; Hirotoshi Dosaka-Akita; Ichiro Kinoshita
    Cancer science, 2023年05月19日, [国際誌]
    英語, 研究論文(学術雑誌), Comprehensive genomic profiling (CGP) tests have been covered by public insurance in Japan for patients with advanced solid tumors who have completed or are completing standard treatments or do not have them. Therefore, genotype-matched drug candidates are often unapproved or off-label, and improving clinical trial access is critical, involving the appropriate timing of CGP tests. To address this issue, we analyzed the previous treatment data for 441 patients from an observational study on CGP tests discussed by the expert panel at Hokkaido University Hospital between August 2019 and May 2021. The median number of previous treatment lines was two; three or more lines accounted for 49%. Information on genotype-matched therapies was provided to 277 (63%). Genotype-matched clinical trials were ineligible because of an excess number of previous treatment lines or use of specific agents were found in 66 (15%) patients, with the highest proportion in breast and prostate cancers. Many patients met the exclusion criteria of one to two or more treatment lines across cancer types. In addition, previous use of specific agents was a frequent exclusion criterion for breast, prostate, colorectal, and ovarian cancers. The patients with tumor types with a low median number (two or fewer) of previous treatment lines, including most rare cancers, primary unknown cancers, and pancreatic cancers, had significantly fewer ineligible clinical trials. The earlier timing of CGP tests may improve access to genotype-matched clinical trials, with their proportion varying by cancer type. Each relevant society needs to advocate the desirable timing of CGP testing nationwide.
  • Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan
    Yoichi Naito; Kuniko Sunami; Hidenori Kage; Keigo Komine; Toraji Amano; Mitsuho Imai; Takafumi Koyama; Daisuke Ennishi; Masashi Kanai; Hirotsugu Kenmotsu; Takahiro Maeda; Sachi Morita; Daisuke Sakai; Kousuke Watanabe; Hidekazu Shirota; Ichiro Kinoshita; Masashiro Yoshioka; Nobuaki Mamesaya; Mamoru Ito; Shinji Kohsaka; Yusuke Saigusa; Kouji Yamamoto; Makoto Hirata; Katsuya Tsuchihara; Takayuki Yoshino
    JAMA Network Open, 5, 12, e2245081, e2245081, American Medical Association (AMA), 2022年12月05日
    研究論文(学術雑誌), Importance

    Quality assurance of molecular tumor boards (MTBs) is crucial in cancer genome medicine.

    Objective

    To evaluate the concordance of recommendations by MTBs and centrally developed consensus treatment recommendations at all 12 leading institutions for cancer genomic medicine in Japan using 50 simulated cases.

    Design, Setting, and Participants

    This was a prospective quality improvement study of 50 simulated cancer cases. Molecular tumor boards from 12 core hospitals independently recommended treatment for 50 cases blinded to the centrally developed consensus treatment recommendations. The study’s central committee consisted of representatives from all 12 core hospitals in Japan who selected the 50 simulated cases from The Cancer Genome Atlas database, including frequently observed genomic alterations. The central committee recommended centrally developed consensus treatment. The concordance rate for genomically matched treatments between MTBs and centrally developed consensus treatment recommendations was evaluated. Data analysis was conducted from January 22 to March 3, 2021.

    Exposures

    Simulated cases of cancer.

    Main Outcomes and Measures

    The primary outcome was concordance, defined as the proportion of recommendations by MTBs concordant with centrally developed consensus treatment recommendations. A mixed-effects logistic regression model, adjusted for institutes as a random intercept, was applied. High evidence levels were defined as established biomarkers for which the treatment was ready for routine use in clinical practice, and low evidence levels were defined as biomarkers for genomically matched treatment that were under investigation.

    Results

    The Clinical Practice Guidance for Next-Generation Sequencing in Cancer Diagnosis and Treatment (edition 2.1) was used for evidence-level definition. The mean concordance between MTBs and centrally developed consensus treatment recommendations was 62% (95% CI, 57%-65%). Each MTB concordance varied from 48% to 86%. The concordance rate was higher in the subset of patients with colorectal cancer (100%; 95% CI, 94.0%-100%), ROS1 fusion (100%; 95% CI, 85.5%-100%), and high evidence level A/R (A: 88%; 95% CI, 81.8%-93.0%; R:100%; 95% CI, 92.6%-100%). Conversely, the concordance rate was lower in cases of cervical cancer (11%; 95% CI, 3.1%-26.1%), TP53 mutation (16%; 95% CI, 12.5%-19.9%), and low evidence level C/D/E (C: 30%; 95% CI, 24.7%-35.9%; D: 25%; 95% CI, 5.5%-57.2%; and E: 18%; 95% CI, 13.8%-23.0%). Multivariate analysis showed that evidence level (high [A/R] vs low [C/D/E]: odds ratio, 4.4; 95% CI, 1.8-10.8) and TP53 alteration (yes vs no: odds ratio, 0.06; 95% CI, 0.03-0.10) were significantly associated with concordance.

    Conclusions and Relevance

    The findings of this study suggest that genomically matched treatment recommendations differ among MTBs, particularly in genomic alterations with low evidence levels wherein treatment is being investigated. Sharing information on matched therapy for low evidence levels may be needed to improve the quality of MTBs.
  • Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors
    Mitsuho Imai; Yoshiaki Nakamura; Kuniko Sunami; Hidenori Kage; Keigo Komine; Takafumi Koyama; Toraji Amano; Daisuke Ennishi; Masashi Kanai; Hirotsugu Kenmotsu; Takahiro Maeda; Sachi Morita; Daisuke Sakai; Hideaki Bando; Akitaka Makiyama; Tatsuya Suzuki; Makoto Hirata; Shinji Kohsaka; Katsuya Tsuchihara; Yoichi Naito; Takayuki Yoshino
    Cancer Science, Wiley, 2022年09月11日
    研究論文(学術雑誌)
  • Chronological improvement in precision oncology implementation in Japan
    Kuniko Sunami; Yoichi Naito; Keigo Komine; Toraji Amano; Daisuke Ennishi; Mitsuho Imai; Hidenori Kage; Masashi Kanai; Hirotsugu Kenmotsu; Takafumi Koyama; Takahiro Maeda; Sachi Morita; Daisuke Sakai; Shinji Kohsaka; Katsuya Tsuchihara; Yusuke Saigusa; Takayuki Yoshino
    Cancer Science, Wiley, 2022年09月02日
    研究論文(学術雑誌)
  • 進行固形がん患者に対する保険診療による包括的がんゲノムプロファイリング検査の実施時期についての検討
    菊地 順子; 大原 克仁; 天野 虎次; 矢部 一郎; 小松 嘉人; 松野 吉宏; 石黒 敦; 水上 裕輔; 櫻井 晃洋; 木下 一郎
    日本内科学会雑誌, 111, Suppl., 190, 190, (一社)日本内科学会, 2022年02月
    日本語
  • Germline PRDM1 Variant rs2185379 in Long-Term Recurrence-Free Survivors of Advanced Ovarian Cancer.
    Takashi Mitamura; Tianyue Zhai; Kanako C Hatanaka; Yutaka Hatanaka; Toraji Amano; Lei Wang; Shinya Tanaka; Hidemichi Watari
    Pharmacogenomics and personalized medicine, 15, 977, 984, 2022年, [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: To identify the germline genetic characteristics of long-term recurrence-free survivors that can be applied to establishing a new strategy for curing advanced cancer, we investigated the whole-genome single nucleotide variants of ovarian cancer patients. PATIENTS AND METHODS: DNA specimens were obtained from rare long-term recurrence-free survivors with FIGO stage III-IV ovarian cancer with no recurrence for 8-23 years after primary treatments for a whole-genome analysis of approximately 660,000 single nucleotide variants. We then established a mouse model with a notable gene alteration by CRISPR/Cas9 to confirm the biological role. RESULTS: The long-term recurrence-free survivors more frequently had germline heterozygous variant rs2185379 of the PRDM1 gene exon than patients with early recurrence (6.8-fold, P=0.013) and the general population. In the mouse model, primary intraperitoneal disseminated tumors of allograft ID8 were significantly smaller in the germline heterozygous rs2185379 group than in the wild-type group (57.4% decrease, P=0.008). Immunohistochemistry showed that the area of distribution of infiltrating T lymphocytes with positive CD8 staining was significantly increased in the germline heterozygous rs2185379 group in comparison to the wild-type group. CONCLUSION: Germline heterozygous rs2185379 in PRDM1 is correlated with an excellent prognosis and can be used to establish a new strategy for treating advanced ovarian cancer.
  • Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer
    Kanako Hagio; Toraji Amano; Hideyuki Hayashi; Takashi Takeshita; Tomohiro Oshino; Junko Kikuchi; Yoshihito Ohhara; Ichiro Yabe; Ichiro Kinoshita; Hiroshi Nishihara; Hiroko Yamashita
    Scientific Reports, 11, 1, Springer Science and Business Media LLC, 2021年12月, [査読有り]
    研究論文(学術雑誌), AbstractClinical targeted sequencing allows for the selection of patients expected to have a better treatment response, and reveals mechanisms of resistance to molecular targeted therapies based on actionable gene mutations. We underwent comprehensive genomic testing with either our original in-house CLHURC system or with OncoPrime. Samples from 24 patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer underwent targeted sequencing between 2016 and 2018. Germline and somatic gene alterations and patients’ prognosis were retrospectively analyzed according to the response to endocrine therapy. All of the patients had one or more germline and/or somatic gene alterations. Four patients with primary or secondary endocrine-resistant breast cancer harbored germline pathogenic variants of BRCA1, BRCA2, or PTEN. Among somatic gene alterations, TP53, PIK3CA, AKT1, ESR1, and MYC were the most frequently mutated genes. TP53 gene mutation was more frequently observed in patients with primary endocrine resistance compared to those with secondary endocrine resistance or endocrine-responsive breast cancer. Recurrent breast cancer patients carrying TP53-mutant tumors had significantly worse overall survival compared to those with TP53-wild type tumors. Our 160-gene cancer panel will be useful to identify clinically actionable gene alterations in breast cancer in clinical practice.
  • Genetic heterogeneity during breast cancer progression in young patients.
    Kanako Hagio; Kanako C Hatanaka; Toraji Amano; Yoshihiro Matsuno; Yutaka Hatanaka; Hiroko Yamashita
    Breast (Edinburgh, Scotland), 60, 206, 213, 2021年10月28日, [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Because a number of years may be required for normal cells to develop into carcinoma, genes involved in tumorigenesis and progression might differ among breast cancers in young women and those in older women. The present study sought to analyze subclonality during breast cancer evolution as well as diversity within each individual in our young patients' cohort. METHODS: A total of 13 women aged <35 years at diagnosis with early breast cancer were recruited. Serial sections of breast samples consisting of synchronous invasive carcinoma, adjacent ductal carcinoma in situ (DCIS), normal breast tissue, and metastatic lymph nodes were collected and prepared for immunohistochemical analysis of estrogen receptor, progesterone receptor, HER2, and Ki67, and for extraction of genomic DNA. Germline and somatic gene alterations of genomic DNA were examined by targeted sequencing. RESULTS: Genomic DNA from 13 blood samples and 36 breast tissues consisting of 14 invasive carcinomas, nine adjacent DCIS, 11 normal breast tissues, and two metastatic lymph nodes were successfully sequenced. Germline gene alterations including pathogenic variants and gene alterations that were not yet evaluated for their clinical significance were detected in all patients but one. Somatic gene alterations were identified in eight invasive carcinomas, five DCIS, and one metastatic lymph node. Different somatic gene alterations between invasive carcinoma and DCIS were detected in two patients. Somatic gene mutations were present in non-neoplastic tissues in three patients. No two patients had the same gene alterations. CONCLUSION: Our results reveal diversity within each individual during breast cancer progression.
  • [Development of a System for Providing Cancer Genomic Medicine in Hokkaido-From the Standpoint of a Designated Core Hospital for Cancer Genomic Medicine].
    Ichiro Kinoshita; Junko Kikuchi; Yoshihito Ohhara; Toraji Amano; Hirotoshi Akita
    Gan to kagaku ryoho. Cancer & chemotherapy, 48, 7, 882, 886, 2021年07月, [国内誌]
    日本語, 研究論文(学術雑誌), Hokkaido University Hospital has been designated as a Core Hospital for Cancer Genomic Medicine and developed a system to provide cancer genomic medicine in Hokkaido with its liaison hospitals. Since being reimbursed in June 2019, comprehensive cancer genome profiling (CGP) testing showed certain therapeutic efficacy in patients with no standard treatment options, but it also revealed some problems such as the small number of patients who can receive therapeutic drugs matched with gene abnormalities. Since candidate drugs are often unapproved or off-label, it is necessary to smoothly introduce clinical trials, advanced medical treatment system, and patient-proposed health care service. At our hospital, we are focusing on sharing information on clinical trials being conducted in Hokkaido, launching investigator-initiated clinical trials, promoting patient-proposed health care service, promoting a registry study of genetic profiling and targeted therapies in patients with rare cancers and accompanying clinical trials, and incorporating pediatric cancer patients. This paper describes Hokkaido's cancer genomic medicine provision system, including its exit strategy, and the human resource development that serve as its foundation.
  • がん遺伝子パネル検査を用いた乳癌進展における遺伝子異常の検討
    萩尾 加奈子; 竹下 卓志; 押野 智博; 守谷 結美; 李 東; 天野 虎次; 畑中 佳奈子; 畑中 豊; 山下 啓子
    日本乳癌学会総会プログラム抄録集, 29回, 23, 23, (一社)日本乳癌学会, 2021年07月
    日本語
  • Correction to: The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan.
    Kuniko Sunami; Yoichi Naito; Eriko Aimono; Toraji Amano; Daisuke Ennishi; Hidenori Kage; Masashi Kanai; Keigo Komine; Takafumi Koyama; Takahiro Maeda; Sachi Morita; Daisuke Sakai; Shinji Kohsaka; Katsuya Tsuchihara; Takayuki Yoshino
    International journal of clinical oncology, 26, 5, 1007, 1007, 2021年05月, [国内誌]
    英語
  • Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan
    Junko Kikuchi; Yoshihito Ohhara; Kohichi Takada; Hiroki Tanabe; Kazuteru Hatanaka; Toraji Amano; Kanako C Hatanaka; Yutaka Hatanaka; Takashi Mitamura; Momoko Kato; Yuka Shibata; Ichiro Yabe; Akira Endoh; Yoshito Komatsu; Yoshihiro Matsuno; Minako Sugiyama; Atsushi Manabe; Akihiro Sakurai; Masato Takahashi; Hirohito Naruse; Yoshihiro Torimoto; Hirotoshi Dosaka-Akita; Ichiro Kinoshita
    Japanese Journal of Clinical Oncology, 51, 5, 753, 761, Oxford University Press (OUP), 2021年04月30日, [査読有り]
    研究論文(学術雑誌), Abstract

    Background
    Comprehensive cancer genomic profiling has been used recently for patients with advanced solid cancers. Two cancer genomic profiling tests for patients with no standard treatment are covered by Japanese public health insurance since June 2019.




    Methods
    We prospectively analyzed data of 189 patients with solid cancers who underwent either of the two-cancer genomic profiling tests at Hokkaido University Hospital and its liaison hospitals and whose results were discussed in molecular tumor board at Hokkaido University Hospital between August 2019 and July 2020.




    Results
    All 189 patients had appropriate results. Actionable gene alterations were identified in 93 patients (49%). Frequent mutations included PIK3CA (12%) mutation, BRCA1/2 alteration (7%), ERBB2 amplification (6%) and tumor mutation burden-High (4%). The median turnaround time from sample shipping to acquisition by the expert panel was 26 days. Although 115 patients (61%) were provided with information for genotype-matched therapies, only 21 (11%) received them. Notably, four of eight patients below the age of 20 years were provided information for genotype-matched therapies, and three received them. Their response rates and disease control rates were 29% and 67%, respectively. Most patients who did not undergo the genotype-matched therapies were provided information for only investigational drugs in phases I and II at distant clinical trial sites in central Japan. Twenty-six patients were informed of suspected germline findings, while 11 patients (42%) received genetic counseling.




    Conclusions
    The publicly reimbursed cancer genomic profilings may lead to the modest but favorable therapeutic efficacy of genotype-matched therapy for solid cancer patients with no standard therapy. However, poor access to genotype-matched therapy needs to be resolved.


  • Stratification of Postoperative Prognosis by Invasive Tumor Thickness in Perihilar Cholangiocarcinoma
    Mitsunobu Oba; Yoshitsugu Nakanishi; Toraji Amano; Keisuke Okamura; Takahiro Tsuchikawa; Toru Nakamura; Takehiro Noji; Toshimichi Asano; Kimitaka Tanaka; Satoshi Hirano
    Annals of Surgical Oncology, 28, 4, 2001, 2009, Springer Science and Business Media LLC, 2021年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The pathological tumor classification of distal cholangiocarcinoma in the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th edition is based on invasive depth, whereas that of perihilar cholangiocarcinoma (PHCC) continues to be layer-based. We aimed to clarify whether invasive depth measurement based on invasive tumor thickness (ITT) could help determine postoperative prognosis in patients with PHCC. METHODS: We enrolled 184 patients with PHCC who underwent hepatectomy plus extrahepatic bile duct resection or hepatopancreatoduodenectomy with curative intent. ITT was measured using simple definitions according to the sectioning direction or gross tumor pattern. RESULTS: The median ITT was 5.8 mm (range 0.7-15.5). Using the recursive partitioning technique, ITT was classified into grades A (ITT < 2 mm, n = 9), B (2 mm ≤ ITT < 5 mm, n = 68), C (5 mm ≤ ITT < 11 mm, n = 81), and D (11 mm < ITT, n = 26). The median survival times (MSTs) in patients with grade B, C, or D were 90.8, 44.6, and 21.1 months, respectively (patients with grade A did not reach the MST). There were significant differences in postoperative prognosis between ITT grades (A vs. B, p = 0.027; B vs. C, p < 0.001; C vs. D, p = 0.004). Through multivariate analysis, regional node metastasis, invasive carcinoma at the resected margin, and ITT grade were determined as independent prognostic factors. CONCLUSION: ITT could be measured using simple methods and may be used to stratify postoperative prognosis in patients with PHCC.
  • The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan
    Kuniko Sunami; Yoichi Naito; Eriko Aimono; Toraji Amano; Daisuke Ennishi; Hidenori Kage; Masashi Kanai; Keigo Komine; Takafumi Koyama; Takahiro Maeda; Sachi Morita; Daisuke Sakai; Shinji Kohsaka; Katsuya Tsuchihara; Takayuki Yoshino
    International Journal of Clinical Oncology, 26, 3, 443, 449, Springer Science and Business Media LLC, 2021年03月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), Abstract
    Background
    Since June 2019, cancer genomic profiling (CGP) tests have been reimbursed by the National Health Insurance system in Japan, with restrictions for government-designated hospitals with a molecular tumor board composed of multidisciplinary specialists, known as an expert panel (EP). The standardization of EPs is a critical challenge for implementing precision oncology in the clinical setting.



    Methods
    Data on consecutive cases who underwent the CGP tests at 11 core hospitals between June 2019 and January 2020 were collected. We evaluated the proportions of cases that received genomically matched treatments, including investigational new drugs (INDs) based on CGP results, and/or for which genetic counseling was recommended. Two simulated cases were annotated by each EP. The annotated reports were then centrally assessed.



    Results
    Each EP mainly discussed the applicability to genomically matched treatments and the necessity of performing genetic counseling. A pre-review of the report by key members in each EP reportedly made the EP conference more interactive and efficient, and thereby saved time. A total of 747 cases underwent CGP tests, 28 cases (3.7%) received genomically matched treatment, and 17 cases (2.3%) were referred for genetic counseling. Annotated reports for the simulated cases varied across the EPs, particularly the number of recommended IND trials, which seemed to be associated with the actual number of participants in IND trials.



    Conclusions
    This investigation provides reference data for the application of precision oncology in a clinical setting. Further investigations on the standardization of clinical annotations are warranted.


  • Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)
    Yoichi Naito; Hiroyuki Aburatani; Toraji Amano; Eishi Baba; Toru Furukawa; Tetsu Hayashida; Eiso Hiyama; Sadakatsu Ikeda; Masashi Kanai; Motohiro Kato; Ichiro Kinoshita; Naomi Kiyota; Takashi Kohno; Shinji Kohsaka; Keigo Komine; Itaru Matsumura; Yuji Miura; Yoshiaki Nakamura; Atsushi Natsume; Kazuto Nishio; Katsutoshi Oda; Naoyuki Oda; Natsuko Okita; Kumiko Oseto; Kuniko Sunami; Hideaki Takahashi; Masayuki Takeda; Shimon Tashiro; Shinichi Toyooka; Hideki Ueno; Shinichi Yachida; Takayuki Yoshino; Katsuya Tsuchihara
    International Journal of Clinical Oncology, 26, 2, 233, 283, Springer Science and Business Media LLC, 2021年02月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), Abstract
    Background
    To promote precision oncology in clinical practice, the Japanese Society of Medical Oncology, the Japanese Society of Clinical Oncology, and the Japanese Cancer Association, jointly published “Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment” in 2017. Since new information on cancer genomic medicine has emerged since the 1st edition of the guidance was released, including reimbursement for NGS-based multiplex gene panel tests in 2019, the guidance revision was made.



    Methods
    A working group was organized with 33 researchers from cancer genomic medicine designated core hospitals and other academic institutions. For an impartial evaluation of the draft version, eight committee members from each society conducted an external evaluation. Public comments were also made on the draft. The finalized Japanese version was published on the websites of the three societies in March 2020.



    Results
    The revised edition consists of two parts: an explanation of the cancer genomic profiling test (General Discussion) and clinical questions (CQs) that are of concern in clinical practice. Particularly, patient selection should be based on the expectation that the patient's post-test general condition and organ function will be able to tolerate drug therapy, and the optimal timing of test should be considered in consideration of subsequent treatment plans, not limited to treatment lines.



    Conclusion
    We expect that the revised version will be used by healthcare professionals and will also need to be continually reviewed in line with future developments in cancer genome medicine.


  • Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Jun Taguchi; Yasushi Shimizu; Shin Ariga; Tomohiro Goda; Yoshihito Ohhara; Rio Honma; Takuro Noguchi; Satoshi Takeuchi; Ichiro Kinoshita; Toraji Amano; Takatsugu Mizumachi; Satoshi Kano; Miki Takahara; Takahisa Abe; Akihiro Homma; Hirotoshi Dosaka-Akita
    International Journal of Clinical Oncology, 26, 1, 51, 58, 2021年01月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Prognostic significance of OX40+ lymphocytes in tumor stroma of surgically resected small-cell lung cancer
    Hiroshi Yokouchi; Hiroshi Nishihara; Toshiyuki Harada; Toraji Amano; Takayuki Ohkuri; Shigeo Yamazaki; Hajime Kikuchi; Satoshi Oizumi; Hidetaka Uramoto; Fumihiro Tanaka; Masao Harada; Kenji Akie; Fumiko Sugaya; Yuka Fujita; Kei Takamura; Tetsuya Kojima; Mitsunori Higuchi; Osamu Honjo; Yoshinori Minami; Naomi Watanabe; Masaharu Nishimura; Hiroyuki Suzuki; Hirotoshi Dosaka-Akita; Hiroshi Isobe
    OncoImmunology, 10, 1, 1971430, 1971430, Informa UK Limited, 2021年01月01日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), OX40 (CD134) is a co-stimulatory molecule mostly expressed on activated T lymphocytes. Previous reports have shown that OX40 can be an immuno-oncology target and a clinical biomarker for cancers of various organs. In this study, we collected formalin-fixed paraffin-embedded tumor samples from 124 patients with small-cell lung cancer (SCLC) who had undergone surgery. We analyzed the expression profiles of OX40 and other relevant molecules, such as CD4, CD8, and Foxp3, in tumor stroma and cancer nest using immunohistochemistry and investigated their association with survival. High infiltration of OX40+ lymphocytes (OX40high) in tumor stroma was positively associated with relapse-free survival (RFS) and overall survival (OS) compared with low infiltration of OX40+ lymphocytes (OX40low) (RFS, median, 26.0 months [95% confidence interval (CI), not reached (NR)-NR] vs 13.2 months [9.1-17.2], p = .024; OS, NR [95% CI, NR-NR] vs 29.8 months [21.3-38.2], p = .049). Multivariate analysis revealed that OX40high in tumor stroma was an independent indicator of prolonged RFS. Moreover, RFS of patients with OX40high/CD4high in tumor stroma was significantly longer than that of patients with OX40low/CD4low. The RFS of patients with tumor stroma with OX40high/CD8high was significantly longer than that of patients with tumor stroma with OX40low/CD8high, OX40high/CD8low, or OX40low/CD8low. These findings suggest that OX40+ lymphocytes in tumor stroma play a complementary role in regulating the relapse of early-stage SCLC. Reinforcing immunity by coordinating the recruitment of OX40+ lymphocytes with CD4+ and CD8+ T cells in tumor stroma may constitute a potential immunotherapeutic strategy for patients with SCLC.
  • IRIS/Bev療法時の下痢に対する半夏瀉心湯予防投与の第二相試験 生存期間の解析
    原田 一顕; 中積 宏之; 川本 泰之; 結城 敏志; 石黒 敦; 舘山 美樹; 宮城島 拓人; 中村 路夫; 太宰 昌佳; 奥田 博介; 畑中 一映; 天野 虎次; 小松 嘉人
    日本癌治療学会学術集会抄録集, 58回, P, 122, (一社)日本癌治療学会, 2020年10月
    英語
  • ゲノム医療の現状-がんゲノム医療中核拠点病院のエキスパートパネルからの報告
    内藤 陽一; 角南 久仁子; 坂井 大介; 前田 高宏; 天野 虎次; 小峰 啓吾; 四十物 絵理子; 遠西 大輔; 森田 佐知; 金井 雅史; 鹿毛 秀宣; 小山 隆文; 高阪 真路; 土原 一哉; 吉野 孝之
    日本癌治療学会学術集会抄録集, 58回, O62, 1, (一社)日本癌治療学会, 2020年10月
    英語
  • Time to Recurrence After Surgical Resection and Survival After Recurrence Among Patients with Perihilar and Distal Cholangiocarcinomas
    Yoshitsugu Nakanishi; Keisuke Okamura; Takahiro Tsuchikawa; Toru Nakamura; Takehiro Noji; Toshimichi Asano; Aya Matsui; Kimitaka Tanaka; Soichi Murakami; Yuma Ebihara; Yo Kurashima; Hajime Narasaki; Toraji Amano; Toshiaki Shichinohe; Satoshi Hirano
    Annals of Surgical Oncology, 27, 11, 4171, 4180, Springer Science and Business Media LLC, 2020年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The differences between perihilar cholangiocarcinoma (PHCC) and distal cholangiocarcinoma (DCC) regarding recurrence and the factors that affect recurrence after surgery are unclear. This study aims to investigate the differences in recurrence patterns between patients with PHCC and those with DCC after surgical resection with curative intent. It also investigates the risk factors associated with recurrence and survival thereafter. PATIENTS AND METHODS: The postoperative courses of 366 patients with extrahepatic cholangiocarcinomas (EHCCs), including 236 with PHCC and 130 with DCC, who underwent surgical resections were investigated retrospectively. RESULTS: During follow-up, tumors recurred in 143 (60.6%) patients with PHCC and in 72 (55.4%) patients with DCC. Overall survival (OS) after surgery, recurrence-free survival (RFS), and OS after recurrence were similar for the patients with PHCC and those with DCC. The cumulative probability of recurrence declined 3 years after surgery in the patients with PHCC and those with DCC. A multivariable analysis determined that, among the patients with PHCC and those with DCC, regional lymph node metastasis was a significant risk factor associated with RFS. Ten patients with PHCC and eight patients with DCC with two or fewer sites of recurrence in a single organ underwent resections. A multivariable analysis determined that recurrent tumor resection was an independent prognostic factor associated with OS after recurrence in the patients with PHCC and those with DCC. CONCLUSIONS: Postoperative survival did not differ between the patients with PHCC and those with DCC. Frequent surveillances for recurrence are needed for 3 years after surgical resection of EHCCs. In selected patients, surgery for recurrent EHCCs might be associated with improved outcomes.
  • Clinical impact of a cancer genomic profiling test using an in‐house comprehensive targeted sequencing system
    Hideyuki Hayashi; Shigeki Tanishima; Kyoko Fujii; Ryo Mori; Chihiro Okada; Emmy Yanagita; Yuka Shibata; Ryosuke Matsuoka; Toraji Amano; Takahiro Yamada; Ichiro Yabe; Ichiro Kinoshita; Yoshito Komatsu; Hirotoshi Dosaka‐Akita; Hiroshi Nishihara
    Cancer Science, 111, 10, 3926, 3937, Wiley, 2020年10月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Precision medicine is a promising strategy for cancer treatment. In this study, we developed an in-house clinical sequencing system to perform a comprehensive cancer genomic profiling test as a clinical examination and analyzed the utility of this system. Genomic DNA was extracted from tumor tissues and peripheral blood cells collected from 161 patients with different stages and types of cancer. A comprehensive targeted amplicon exome sequencing for 160 cancer-related genes was performed using next-generation sequencing (NGS). The sequencing data were analyzed using an original bioinformatics pipeline, and multiple cancer-specific gene alterations were identified. The success rate of our test was 99% (160/161), while re-biopsy was required for 24% (39/161) of the cases. Potentially actionable and actionable gene alterations were detected in 91% (145/160) and 46% (73/160) of the patients, respectively. The actionable gene alterations were frequently detected in PIK3CA (9%), ERBB2 (8%), and EGFR (4%). High tumor mutation burden (TMB) (≥10 mut/Mb) was observed in 12% (19/160) of the patients. The secondary findings in germline variants considered to be associated with hereditary tumors were detected in 9% (15/160) of the patients. Seventeen patients (11%, 17/160) were treated with genotype-matched therapeutic agents, and the response rate was 47% (8/17). The median turnaround time for physicians was 20 days, and the median survival time after the initial visit was 8.7 months. The results of the present study prove the feasibility of implementing in-house clinical sequencing as a promising laboratory examination technique for precision cancer medicine.
  • A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703)
    Shin-ichi Fukumoto; Satoshi Oizumi; Masao Harada; Noriaki Sukoh; Kosuke Nakano; Satoshi Fuke; Jun Sakakibara-Konishi; Kei Takamura; Kenichiro Ito; Yuka Fujita; Yutaka Nishigaki; Toshiyuki Harada; Kenji Akie; Ichiro Kinoshita; Toraji Amano; Hiroshi Isobe; Hirotoshi Dosaka-Akita; Masaharu Nishimura
    Cancer Chemotherapy and Pharmacology, 86, 1, 117, 127, Springer Science and Business Media LLC, 2020年07月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), PURPOSE: This study evaluated the efficacy and safety of platinum plus gemcitabine (P/G) combinations as postoperative adjuvant chemotherapies for non-small cell lung cancer. METHODS: Patients with postoperative stage IB-IIIA non-small cell lung cancer were randomly assigned to receive either cisplatin plus gemcitabine (GP arm) or carboplatin plus gemcitabine (GC arm) every 3 weeks for four cycles. The primary endpoint was 2-year disease-free survival (DFS). Secondary endpoints were safety, feasibility, overall survival (OS), and biomarker analyses. RESULTS: A total of 102 patients were randomized (stage IB, 22%; II, 36%; IIIA, 42%; histology: 74% adenocarcinoma). Of the 51 patients in each arm, 37 (73%) completed 4 cycles. During follow-up (median 5.8 years; range 0.1-9.7 years), estimated DFS and OS rates at 2 years were 59.6% and 86.3% with GP and 68.0% and 86.3% with GC, respectively. No significant difference in DFS was noted between arms (P = 0.163), although 3-, 4-, and 5-year DFS rates were higher with GC. Hematological toxic effects were comparable and non-hematological toxic effects were infrequent. DFS was significantly higher in the excision repair cross-complementation group 1 (ERCC1)-low group than in the ERCC1-high group for the GP arm (P = 0.045). CONCLUSION: Both P/G combination regimens were feasible and well-tolerated, and thus may represent valid options for postoperative adjuvant treatment of non-small cell lung cancer. Although no significant differences in DFS were evident between regimens, the present data favor the adoption of GC for further evaluation. CLINICAL TRIAL REGISTRATION: UMIN-CTR ( https://www.umin.ac.jp/ctr/ ) identifier: UMIN000000913.
  • Risk Factors for Delayed Bleeding after Therapeutic Gastrointestinal Endoscopy in Patients Receiving Oral Anticoagulants: A Multicenter Retrospective Study
    Kimitoshi Kubo; Mototsugu Kato; Katsuhiro Mabe; Naohiko Harada; Yoichiro Iboshi; Takashi Kagaya; Masayoshi Ono; Tatsuya Toyokawa; Haruhiro Yamashita; Toshio Kuwai; Hiroshige Hamada; Yuko Sakakibara; Hitoshi Nishiyama; Nobuyuki Ara; Hideki Mori; Mio Matsumoto; Yasuo Takahashi; Shinji Katsushima; Noriko Watanabe; Yoshito Ogura; Hiroki Saito; Eiji Masuda; Toraji Amano
    Digestion, 102, 2, 1, 9, S. Karger AG, 2019年09月10日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND/AIMS: Delayed bleeding is among the adverse events associated with therapeutic gastrointestinal endoscopy. The aim of this study was to evaluate risk factors for delayed bleeding after gastrointestinal endoscopic resection in patients receiving oral anticoagulants as well as to compare the rates of occurrence of delayed bleeding between the oral anticoagulants used. METHODS: We retrospectively analyzed a total of 772 patients receiving anticoagulants. Of these, 389 and 383 patients were receiving direct oral anticoagulants (DOACs) and warfarin, respectively. Therapeutic endoscopic procedures performed included endoscopic submucosal dissection (ESD), endoscopic mucosal resection, polypectomy, and cold polypectomy. RESULTS: Delayed bleeding occurred in 90 patients (11.7%) with no significant difference between the DOAC and warfarin groups (9.5 and 13.8%, respectively). Delayed bleeding occurred significantly more frequently with apixaban than with rivaroxaban (13.5 vs. 6.4%; p < 0.05). A multivariate analysis identified continued anticoagulant therapy (OR 2.29), anticoagulant withdrawal with heparin bridging therapy (HBT; OR 2.18), anticoagulant therapy combined with 1 antiplatelet drug (OR 1.72), and ESD (OR 3.87) as risk factors for delayed bleeding. CONCLUSION: This study identified continued anticoagulant therapy, anticoagulant withdrawal with HBT, anticoagulant therapy combined with 1 antiplatelet drug, and ESD as risk factors for delayed bleeding after therapeutic endoscopy in patients receiving oral anticoagulants. Delayed bleeding rates were not significantly different between those receiving DOACs and warfarin. It was also suggested that the occurrence of delayed bleeding may vary between different DOACs and that oral anticoagulant withdrawal should be minimized during therapeutic gastrointestinal endoscopy, given the thromboembolic risk involved.
  • Impact of tumour budding grade in 310 patients who underwent surgical resection for extrahepatic cholangiocarcinoma
    Mariko Ogino; Yoshitsugu Nakanishi; Tomoko Mitsuhashi; Yutaka Hatanaka; Toraji Amano; Katsuji Marukawa; Takeo Nitta; Takashi Ueno; Masato Ono; Shota Kuwabara; Tooru Yamada; Satoshi Hirano
    Histopathology, 74, 6, 861, 872, Wiley, 2019年05月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), AIMS: Tumour budding is a risk factor for poor prognosis in various cancers. Tumour buds may present an epithelial-mesenchymal transition (EMT) morphological phenotype. This study aimed to elucidate the prognostic impact of tumour budding grade and its association with clinicopathological and EMT-related features in perihilar cholangiocarcinoma (PHCC) or distal cholangiocarcinoma (DCC). METHODS AND RESULTS: Subjects included 195 PHCC and 115 DCC patients. The numbers of tumour buds in different patients were stratified for postoperative survival using the recursive partitioning technique. Consequently, the numbers of tumour buds in PHCC patients were classified into three grades; namely, low (0-4 buds); intermediate (5-11 buds); and high (≥12 buds); those of DCC patients were classified into two grades; namely, low (0-4 buds) and high (≥5 buds). In both PHCC and DCC patients, high tumour budding grade was associated with poor histological differentiation, higher pT factor, presence of lymphatic, venous, perineural invasion and regional lymph node metastasis. In PHCC patients, residual invasive tumour in the resected margin was also associated with high tumour budding grade. For both PHCC and DCC patients, high tumour budding grade was an independent adverse prognostic factor in multivariate analysis (P < 0001 and P = 0.046, respectively). Immunohistochemical examination revealed that the number of tumour buds increased in patients with tumours showing a mesenchymal profile (negative for E-cadherin and positive for vimentin). CONCLUSIONS: Higher tumour budding grade is associated with invasive clinicopathological features, adverse postoperative prognosis and EMT status in extrahepatic cholangiocarcinoma.
  • Quantitative detection of IKZF 1 deletion by digital PCR in patients with acute lymphoblastic leukemia
    Junichi Hashiguchi; Masahiro Onozawa; Kohei Okada; Toraji Amano; Kanako C. Hatanaka; Hiroshi Nishihara; Norihiro Sato; Takanori Teshima
    International Journal of Laboratory Hematology, 41, 2, e38, e40, Wiley, 2019年04月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)
    Taichi Takashina; Hajime Asahina; Satoshi Oizumi; Noriyuki Yamada; Masao Harada; Kei Takamura; Hiroshi Yokouchi; Toshiyuki Harada; Osamu Honjo; Takahiro Ogi; Naoto Morikawa; Ichiro Kinoshita; Ryoichi Honda; Kosuke Nakano; Kenya Kanazawa; Toraji Amano; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Masaharu Nishimura
    International Journal of Clinical Oncology, 23, 6, 1060, 1069, Springer Science and Business Media LLC, 2018年12月, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: This study evaluated the efficacy and safety of switch maintenance erlotinib and bevacizumab after induction therapy with carboplatin/pemetrexed/bevacizumab for non-squamous non-small cell lung cancer (NSCLC) with wild-type EGFR. METHODS: Enrolled patients had treatment-naïve, advanced non-squamous NSCLC with wild-type EGFR. Carboplatin [area under the curve (AUC) 5.0], pemetrexed (500 mg/m2) and bevacizumab (15 mg/kg) were administered on day 1 every 3 weeks for 4-6 cycles. Maintenance therapy with erlotinib (150 mg/body) on day 1 through 21 plus bevacizumab on day 1 every 3 weeks was continued until disease progression or unacceptable toxicity. The primary endpoint was 6-month progression-free survival (PFS); secondary endpoints included overall survival (OS), overall response rate (ORR), toxicity, and quality of life (QOL). RESULTS: Fifty-one patients were enrolled between September 2011 and June 2014. The median number of cycles for induction and maintenance therapy was 4 (range 1-6) and 4 (range 1-20). Twenty-nine patients (58%) received maintenance therapy. The 6-month PFS rate was 59.5% [95% confidence interval (CI) 45.0-72.6%]. The ORR was 48.0% (95% CI 34.8-61.5%), and disease control rate was 86.0% (95% CI 73.8-93.0%). The median PFS and OS were 6.5 months (95% CI 5.8-7.2 months) and 21.4 months (95% CI 15.9-26.9 months), respectively. Although grades ≥ 3 adverse events were observed in 33 patients (66.0%), most were hematologic; there was no febrile neutropenia. QOL was maintained throughout treatment. CONCLUSIONS: Carboplatin/pemetrexed/bevacizumab followed by erlotinib and bevacizumab maintenance showed modest efficacy and was well tolerated in non-squamous NSCLC patients with wild-type EGFR. TRIAL REGISTRATION: UMIN000005872.
  • Genomic testing for pancreatic cancer in clinical practice as real-world evidence.
    Hideyuki Hayashi; Shigeki Tanishima; Kyoko Fujii; Ryo Mori; Yasunobu Okamura; Emmy Yanagita; Ryosuke Matsuoka; Toraji Amano; Ichiro Kinoshita; Yoshito Komatsu; Hirotoshi Dosaka-Akita; Hiroshi Nishihara
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 18, 6, 647, 654, Elsevier BV, 2018年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Precision medicine guided by comprehensive genome sequencing represents a potential treatment strategy for pancreatic cancer. However, clinical sequencing for pancreatic cancer entails several practical difficulties. We have launched an in-house clinical sequencing system and started genomic testing for patients with cancer in clinical practice. We have analyzed the clinical utility of this system in pancreatic cancer. METHODS: We retrospectively reviewed 20 patients with pancreatic cancer who visited our division. Genomic DNA was extracted from both tumor tissue and peripheral blood mononuclear cells obtained from the patients. We performed a comprehensive genomic testing using targeted amplicon sequencing for 160 cancer-related genes. The primary endpoints were the detection rates of potential actionable and druggable gene alterations. The secondary endpoints were the detection rate of secondary germline findings, the rate of re-biopsy required for genome sequencing, survival time after the initial visit (post-sequencing survival time), and turnaround time. RESULTS: Although re-biopsy was required for 25% (5/20) of all patients, genomic testing was performed in all patients. Actionable and druggable gene alterations were detected in 100% (20/20) and 35% (7/20) of patients, respectively, whereas secondary germline findings were detected in 5% (1/20) of patients. The median turnaround times for physicians and patients were 20 and 26 days, respectively. The median post-sequencing survival time was 10.3 months. Only 10% (2/20) of all patients were treated with therapeutic agents based on the outcomes of genomic testing. CONCLUSIONS: The clinical application of comprehensive genomic testing for pancreatic cancer was feasible and promising in clinical practice.
  • Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials
    Toshiyuki Harada; Toraji Amano; Tomoo Ikari; Kei Takamura; Takahiro Ogi; Toshiaki Fujikane; Yuka Fujita; Kageaki Taima; Hisashi Tanaka; Takaaki Sasaki; Shunsuke Okumura; Shunichi Sugawara; Hiroshi Yokouchi; Noriyuki Yamada; Naoto Morikawa; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Masaharu Nishimura
    Frontiers in Pharmacology, 8, 972, 972, Frontiers Media SA, 2018年01月16日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), The herbal medicine rikkunshito has the potential to improve chemotherapy-induced nausea and vomiting (CINV) by stimulating ghrelin secretion. We aimed to evaluate the efficacy and safety of rikkunshito in preventing CINV for patients with lung cancer. Two separate prospective, randomized, phase II parallel design studies were conducted in patients with lung cancer. Fifty-eight and sixty-two patients scheduled to receive highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC), respectively, were randomized 1:1 to receive either standard antiemetic therapy in accordance with international guidelines (S group) or standard antiemetic therapy plus oral rikkunshito (R group). The primary endpoint was overall complete response (CR)-that is, no emesis and rescue medication in the first 120 h post-chemotherapy. Secondary endpoints included CR in the acute (0-24 h) and delayed (>24-120 h) phases and safety. Fifty-seven patients (S group, 28; R group, 29) receiving HEC and sixty-two patients (S group, 30; R group, 32) receiving MEC with comparable characteristics were evaluated. The CR rates were similar across the S and R groups for the HEC study in the overall (67.9% vs. 62.1%), acute (96.4% vs. 89.6%), and delayed (67.9% vs. 62.1%) phases, respectively, and for the MEC study in the overall (83.3% vs. 84.4%), acute (100% vs. 100%), and delayed (83.3% vs. 84.4%) phases, respectively. No severe adverse events were observed. Although rikkunshito was well tolerated, it did not demonstrate an additional preventative effect against CINV in lung cancer patients receiving HEC or MEC. Clinical Trial Registry Information: This study is registered with the University Hospital Medical Information Network (UMIN) Clinical Trial Registry, identification numbers UMIN 000014239 and UMIN 000014240.
  • A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
    Yasuyuki Ikezawa; Hajime Asahina; Satoshi Oizumi; Masahiro Watanabe; Kei Takamura; Yasutaka Kawai; Noriyuki Yamada; Toshiyuki Harada; Ichiro Kinoshita; Yuka Fujita; Eisaku Miyauchi; Takahiro Ogi; Toraji Amano; Megumi Furuta; Jun Sakakibara-Konishi; Hiroshi Nishihara; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Masaharu Nishimura
    Cancer chemotherapy and pharmacology, 80, 5, 955, 963, 2017年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • 肺癌の高度催吐性化学療法(HEC)時の悪心・嘔吐(CINV)予防に対する六君子湯の有用性に関する検討(HOT1402)
    猪狩 智生; 原田 敏之; 天野 虎次; 藤田 結花; 田中 寿志; 佐々木 高明; 高村 圭; 菅原 俊一; 秋田 弘俊; 磯部 宏; 西村 正治
    Palliative Care Research, 12, Suppl., S332, S332, (NPO)日本緩和医療学会, 2017年06月
    日本語
  • 肺癌の中等度催吐性化学療法(MEC)時の悪心・嘔吐(CINV)予防に対する六君子湯の有用性に関する検討(HOT1403)
    藤田 結花; 原田 敏之; 天野 虎次; 高村 圭; 田中 寿志; 横内 浩; 佐々木 高明; 秋田 弘俊; 磯部 宏; 西村 正治
    Palliative Care Research, 12, Suppl., S504, S504, (NPO)日本緩和医療学会, 2017年06月
    日本語
  • 肺癌の高度催吐性化学療法(HEC)時の悪心・嘔吐(CINV)予防に対する六君子湯の有用性に関する検討(HOT1402)
    田中 寿志; 原田 敏之; 天野 虎次; 藤田 結花; 佐々木 高明; 高村 圭; 菅原 俊一; 秋田 弘俊; 磯部 宏; 西村 正治
    日本呼吸器学会誌, 6, 増刊, 284, 284, (一社)日本呼吸器学会, 2017年03月
    日本語
  • 肺癌の中等度催吐性化学療法(MEC)時の悪心・嘔吐(CINV)予防に対する六君子湯の有用性に関する検討(HOT1403)
    佐々木 高明; 原田 敏之; 天野 虎次; 高村 圭; 田中 寿志; 横内 浩; 藤田 結花; 秋田 弘俊; 磯部 宏; 西村 正治; 北海道肺癌臨床研究会
    日本呼吸器学会誌, 6, 増刊, 284, 284, (一社)日本呼吸器学会, 2017年03月
    日本語
  • Liver elasticity measurement before and after biliary drainage in patients with obstructive jaundice : a prospective cohort studya prospective cohort study
    Kubo Kimitoshi; Kawakami Hiroshi; Kuwatani Masaki; Nishida Mutsumi; Kawakubo Kazumichi; Kawahata Shuhei; Taya Yoko; Kubota Yoshimasa; Amano Toraji; Shirato Hiroki; Sakamoto Naoya
    BMC gastroenterology, 16, 1, 65, 65, BioMed Central, 2016年12月, [査読有り]
    英語, 研究論文(学術雑誌), Background: Obstructive jaundice has been reported to influence liver elasticity, independent of liver fibrosis. The aim of our prospective study was to evaluate the changes in liver elasticity, before and after biliary drainage, in patients with obstructive jaundice, and to evaluate the correlation between elasticity measures and serum markers of liver fibrosis. Methods: This is a prospective cohort study of 20 patients with obstructive jaundice. Liver elasticity was assessed by Transient Elastography (TE) and Virtual Touch (TM) Quantification (VTQ). Serum total bilirubin (T-Bil) level was measured before biliary drainage (Day 0), with measures repeated at 2 days (Day 2) and 7 days (Day 7) after biliary drainage. Serum levels of the following markers of liver fibrosis were also obtained on Day 0 and Day 7: hyaluronic acid (HA), procollagen-III-peptide (P-III-P). Results: T-Bil, TE, and VTQ for the left (VTQ-L) and right (VTQ-R) lobes of the liver were all elevated before biliary drainage, with respective levels, measured at Day 0, of 11.9 +/- 1.5 mg/dl, 12.1 +/- 0.9 kPa, 2.23 +/- 0.10 m/s, and 1.85 +/- 0. 10 m/s. All values decreased on Day 7 after drainage: T-Bil, 4.7 +/- 1.0 mg/dl (P < 0.001); TE, 7.6 +/- 0.6 kPa (P < 0.001); VTQ-L, 1.53 +/- 0.08 m/s (P < 0.001); and VTQ-R, 1.30 +/- 0.05 m/s (P < 0.001). Similar changes were observed in serum markers of liver fibrosis. Liver elasticity measures correlated with serum levels of T-Bil, P-III-P, and HA (r = 0.35-0.67, P < 0.001). Conclusions: This study confirmed decreases in liver elasticity, measured by TE and VTQ, after biliary drainage. Measures of liver elasticity correlated to levels of T-Bil and serum markers of liver fibrosis. (UMIN ID: UMIN00001284313).
  • Erratum to: Liver elasticity measurement before and after biliary drainage in patients with obstructive jaundice: a prospective cohort study.
    Kimitoshi Kubo; Hiroshi Kawakami; Masaki Kuwatani; Mutsumi Nishida; Kazumichi Kawakubo; Shuhei Kawahata; Yoko Taya; Yoshimasa Kubota; Toraji Amano; Hiroki Shirato; Naoya Sakamoto
    BMC gastroenterology, 16, 1, 116, 116, 2016年09月20日, [国際誌]
    英語
  • Risk factors for a high Comprehensive Complication Index score after major hepatectomy for biliary cancer: a study of 229 patients at a single institution
    Yoshitsugu Nakanishi; Takahiro Tsuchikawa; Keisuke Okamura; Toru Nakamura; Eiji Tamoto; Takehiro Noji; Toshimichi Asano; Toraji Amano; Toshiaki Shichinohe; Satoshi Hirano
    HPB, 18, 9, 735, 741, Elsevier BV, 2016年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: The Comprehensive Complication Index (CCI) is a new tool to evaluate the postoperative condition by calculating the sum of all complications weighted by their severity. The aim of this study was to identify independent risk factors for a high CCI score (≥40) in 229 patients after major hepatectomies with biliary reconstruction for biliary cancers. METHODS: The CCI was calculated online via www.assessurgery.com. Independent risk factors were identified by multivariable analysis. RESULTS: 57 (25%) patients were classified as having CCI ≥ 40. On multivariable analysis, volume of intraoperative blood loss (≥2.5 L) (p = 0.004) and combined pancreatoduodenectomy (PD) (p = 0.006) were independent risk factors for CCI ≥ 40. A high level of maximum serum total bilirubin was identified as independent risk factors for a high volume of intraoperative blood loss. Liver failure (p = 0.046) was more frequent in patients with combined PD than in those without. DISCUSSION: Patients who undergo preoperative external biliary drainage for severe jaundice might have impaired production of coagulation factors. When blood loss during liver transection becomes difficult to control, surgeons should consider various strategies, such as second-stage biliary or pancreatic reconstruction. In patients planned to undergo major hepatectomy with combined PD, preoperative portal vein embolization is mandatory to prevent postoperative liver failure.
  • Predictive factors of long head of the biceps tendon disorders—the bicipital groove morphology and subscapularis tendon tear
    Atsushi Urita; Tadanao Funakoshi; Toraji Amano; Yuichiro Matsui; Daisuke Kawamura; Yusuke Kameda; Norimasa Iwasaki
    Journal of Shoulder and Elbow Surgery, 25, 3, 384, 389, Elsevier BV, 2016年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Disorders of the long head of the biceps (LHB) tendon contribute to anterior shoulder pain. Although LHB tendon disorders are associated with rotator cuff disease, distinguishing between biceps and rotator cuff pathology is difficult. The objective was to identify the predictors of LHB tendon disorders associated with a supraspinatus tear. METHODS: In 55 patients (average age, 65 years) undergoing arthroscopic rotator cuff repair, bicipital groove morphology were assessed using computed tomography, and subscapularis tear and bicipital groove effusion were assessed using magnetic resonance imaging, retrospectively. The LHB tendon was evaluated arthroscopically according to the Lafosse classification. Univariate and multivariate ordinal logistic regression analyses were conducted for injury grade with all covariates. RESULTS: The arthroscopic evaluation of the LHB tendon showed that there were 23 shoulders classified as grade 0, 15 as grade 1, and 17 as grade 2. Univariate logistic regression analysis showed that the width and depth, a medial spur of the bicipital groove, and a subscapularis tear were significantly associated with LHB tendon disorders. Multivariate ordinal logistic regression analysis identified a medial spur and subscapularis tear as significant predictors of LHB tendon disorders. CONCLUSIONS: The preoperative computed tomography and magnetic resonance images, notably the presence of a spur on the bicipital groove or a subscapularis tear, were useful for identifying LHB tendon disorders. When these are found in preoperative images, the clinician should evaluate the patient for the presence of an LHB tendon disorder as a pain generator.
  • Observational cohort study of first-line bevacizumab with oxaliplatin or irinotecan and fluoropyrimidines in metastatic colorectal cancer: HGCSG0802-Analysis of early tumor shrinkage (ETS).
    Yuki Satoshi; Nakatsumi Hiroshi; Sawada Kentaro; Kato Takashi; Meguro Takashi; Nakamura Michio; Iwanaga Ichiro; Ehira Nobuyuki; Sonoda Norikazu; Kudo Mineo; Kato Kanji; Sogabe Susumu; Amano Toraji; Ono Kota; Sakamoto Keita; Miyamoto Noriyuki; Kudo Kohsuke; Sakamoto Naoya; Sakata Yuh; Komatsu Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 34, 4, 2016年02月01日, [査読有り]
  • Value of Virtual Touch Quantification Elastography for Assessing Liver Congestion in Patients With Heart Failure
    Takashi Yoshitani; Naoya Asakawa; Mamoru Sakakibara; Keiji Noguchi; Yusuke Tokuda; Kiwamu Kamiya; Hiroyuki Iwano; Satoshi Yamada; Yusuke Kudou; Mutsumi Nishida; Chikara Shimizu; Toraji Amano; Hiroyuki Tsutsui
    Circulation Journal, 80, 5, 1187, 1195, Japanese Circulation Society, 2016年, [査読有り], [国内誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Heart failure (HF) causes organ congestion, which is thought to increase organ stiffness. The virtual touch quantification (VTQ) method can be used to assess liver stiffness in patients with chronic liver diseases. This study aimed to measure liver and kidney stiffness using VTQ and to determine its value for assessing organ congestion in patients with HF. METHODS AND RESULTS: This study included 10 normal subjects and 38 HF patients (age 52.3±16.7 years, left ventricular ejection fraction 27.0±9.4%, plasma B-type natriuretic peptide [BNP] 1,297.3±1,155.1 pg/ml). We investigated the relationships between clinical characteristics and hemodynamics and liver and kidney stiffness, and assessed the effects of medical treatment on these measurements. Liver stiffness was significantly higher in HF patients (1.17±0.13 m/s vs. 2.03±0.91 m/s, P=0.004) compared with normal subjects, but kidney stiffness was similar in both groups. Central venous pressure (CVP) (P=0.021) and BNP (P=0.025) were independent predictive factors for increased liver stiffness in HF patients. Liver stiffness decreased significantly from 2.37±1.09 to 1.27±0.33 m/s (P<0.001) after treatment. Changes in liver stiffness in HF patients significantly correlated with changes in CVP (R=0.636, P=0.014) and cardiac index (R=-0.557, P=0.039) according to univariate analysis, and with changes in CVP in multivariate analysis. CONCLUSIONS: Liver stiffness measured by noninvasive VTQ methods can be used to assess liver congestion and therapeutic effects in patients with HF. (Circ J 2016; 80: 1187-1195).
  • A case of high-grade neuroendocrine carcinoma that improved with bevacizumab plus modified FOLFOX6 as the fourth-line chemotherapy
    Satoshi Takeuchi; Rio Honma; Jun Taguchi; Toraji Amano; Yasushi Shimizu; Ichiro Kinoshita; Kanako Kubota; Yoshihiro Matsuno; Hirotoshi Dosaka-Akita
    Case Reports in Oncology, 4, 2, 260, 266, S. Karger AG, 2011年05月, [査読有り]
    英語, 研究論文(学術雑誌)
  • Necrotizing sarcoid granulomatosis presenting with elevated serum soluble interleukin-2 receptor levels
    T Harada; T Amano; A Takahashi; J Furuya; E Yamaguchi; M Kaji; T Morikawa; T Itoh; M Shimizu; M Nishimura
    RESPIRATION, 69, 5, 468, 470, 2002年09月, [査読有り]
    英語, 研究論文(学術雑誌)
■ その他活動・業績
■ 主な担当授業
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 臨床ゲノミクス概論, 2024年, 修士課程, 医学院
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • ゲノム情報科学特論, 2024年, 修士課程, 情報科学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • ゲノム情報科学特論, 2024年, 博士後期課程, 情報科学研究科
  • ゲノム情報科学特論, 2024年, 博士後期課程, 情報科学院
  • トランスレーショナルリサーチ概論, 2024年, 学士課程, 医学部
■ 共同研究・競争的資金等の研究課題
  • がん免疫療法の効果予測についての検討
    科学研究費助成事業
    2022年04月01日 - 2025年03月31日
    菊地 順子; 畑中 佳奈子; 天野 虎次; 畑中 豊; 木下 一郎
    日本学術振興会, 基盤研究(C), 北海道大学, 22K07292
  • ゲノム・遺伝子変異プロファイル解析を用いた膵癌における新規治療戦略の構築
    科学研究費助成事業 基盤研究(C)
    2020年04月01日 - 2023年03月31日
    浅野 賢道; 中村 透; 土川 貴裕; 平野 聡; 畑中 豊; 畑中 佳奈子; 天野 虎次
    本研究の開始可能時期が新型コロナウイルス感染症の全国的なまん延による緊急事態宣言期間中であり、北海道大学の行動指針(BCP)により新規研究の施行が困難な状況であった。このため、該当研究期間の前半は自主臨床研究審査委員会の審査に向けた書類作成に時間を割いた。ゲノム研究に関する申請は初めてであり、申請書類の作成に時間を要している。現在も継続中である。
    一方で、承認が得られた際に迅速に研究が開始できるように、術前化学療法を受け、北海道大学病院で膵切除術を受けた症例のうち、患者背景、腫瘍マーカーを含む採血データやCT、PET-CTなどの各種検査所見および術後の長期的な経過(転帰)が詳細に入手可能である50例の選定を行った。症例選定に際し、生存期間や再発の有無、術前治療における化学療法レジメンに偏りがないように留意した。生存期間は「1年未満」、「1~3年未満」、「3~5年未満」、「5年以上」の4群に分け、再発に関しては有無だけではなく、無再発生存期間(DFS)にも着目し、「1年未満の再発」、「1~3年未満の再発」、「3年以上の再発」の3群に群分けした。各パラメーターの群分けを細分化すると、より多くの症例が必要となってしまうため、化学療法レジメンでは、膵癌化学療法のkey drugである「5-FU系薬剤」または「nab-Paclitaxel」使用の有無でのみ群分けした。
    また、迅速に精度の高い解析できるよう本研究で使用する各種機器の準備を進めた。特にターゲットシークエンスに用いるIon PGMTMシステム(Thermo Fisher Scientific社)は入念に設定確認を行った。
    日本学術振興会, 基盤研究(C), 北海道大学, 20K09094
  • 卵巣がんの血管新生阻害薬耐性の発生を予防するためのCCR2阻害薬併用療法の開発
    科学研究費助成事業 基盤研究(C)
    2019年04月01日 - 2022年03月31日
    三田村 卓; 渡利 英道; 畑中 佳奈子; 天野 虎次; 畑中 豊
    [ 動物実験 ]
    2019年度に初回治療実験を行った卵巣漿液性癌では、Bevacizumab(BEV) (10 mg/kg)単剤治療群(n=8)、CCR2阻害薬 BMS CCR2 22 (20 mg/kg)単剤治療群(n=8)、コントロール群(n=8)と比較して、BEV(10mg/kg)とBMS CCR2 22 (20 mg/kg)との併用療法群(n=8)で治療効果が有意に改善された。
    このBEVとBMS CCR2 22との相乗効果を追試するため、卵巣明細胞癌1名と卵巣類内膜癌患者1名より摘出した腫瘍をNOGマウスの腹部皮下へ移植して治療実験を行った。明細胞癌モデルでは、BEV (10 mg/kg)単剤治療群(n=5)とBEV (10mg/kg)とBMS CCR2 22(20 mg/kg)との併用療法群(n=5)の2群を設けて治療効果を検討した。5サイクル目終了時点で2群間で治療効果に差を認めなかったが、BMS CCR2 22を40 mg/kgに増量して3サイクル追加治療を行ったところ、併用群で腫瘍の増殖が有意に抑制された。また摘出腫瘍を用いた免疫染色実験により、本腫瘍は血管新生への依存度が低かったことと、併用群では腫瘍細胞自体のCCR2発現が大幅に低下していたことがわかり、血管新生低依存性腫瘍ではBMS CCR2 22の腫瘍細胞CCR2に対する直接効果が存在する可能性が新たに示唆された。類内膜癌モデルも同じプロトコールで治療実験を行なったが、有害事象が強く実験を中止した。


    [ヒト遺伝子解析研究]
    2019年に引き続き患者血液検体の採取を継続している。現時点までに得られたNGS解析結果の一部を遺伝性卵巣癌患者の臨床病理学的特徴に関する多施設共同研究に応用し、BRCA1/2関連遺伝性卵巣癌における病変発生部位および転移部位と遺伝子学的特徴との相関に関する論文を発表した。
    日本学術振興会, 基盤研究(C), 北海道大学, 19K09818
  • 備蓄・緊急投与が可能な人工赤血球製剤の臨床への橋渡し研究
    革新的医療シーズ実用化研究事業
    2018年09月 - 2021年03月
    日本医療研究開発機構, 北海道大学, 研究分担者, 20lk1403022h0003